VF
ATXI

Virtu Financial’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Virtu Financial’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-434
Closed -$38K – 2212
2022
Q4 		$38K Buy
+434
New +$78.7K 0.01% 1134
2022
Q2 		– Sell
-52
Closed -$28K – 2186
2022
Q1 		$28K Buy
+52
New +$38.9K ﹤0.01% 1252
2021
Q3 		– Sell
-23
Closed -$66K – 2063
2021
Q2 		$66K Buy
+23
New +$114K 0.01% 1286
2021
Q1 		– Sell
-16
Closed -$104K – 2119
2020
Q4 		$104K Buy
+16
New +$83.9K 0.01% 1045
2018
Q1 		– Sell
-14
Closed -$58K – 2739
2017
Q4 		$58K Buy
+14
New +$71.4K ﹤0.01% 2051

Other funds holding ATXI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
IWP
Icon Wealth Partners Houston, Texas $880M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial's ATXI Position: Q1 2023 in Review

Virtu Financial sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2023, closing a stake of 434 shares — an estimated $38K sold.

Virtu Financial first reported a position in ATXI in Q4 2017 and held it in 5 quarters. The position peaked at $104K in Q4 2020. 13 funds tracked by Wall St. Rank hold ATXI as of Q1 2023.

  • Virtu Financial reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Virtu Financial sold 434 Avenue Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $38K.
  • Virtu Financial first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2017 and held it in 5 quarters.
  • Virtu Financial's Avenue Therapeutics, Inc. Common Stock position peaked at $104K in Q4 2020.
  • 13 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Virtu Financial's 13F filing for Q1 2023, filed 1 May 2023.